Improving the Prevention and Treatment of Venous Thromboembolism in Cancer: The Strategic Role of the Health-System Pharmacist

PROGRAM P10076E
RELEASE DATE: APRIL 22, 2011 • EXPIRATION DATE: APRIL 22, 2012
ESTIMATED TIME TO COMPLETE: 1.0 HOUR

Download PDF
Click here to complete the posttest and obtain a CE certificate online

TARGET AUDIENCE
This activity was developed for health-system pharmacists and oncology pharmacists.

LEARNING OBJECTIVES
After completing this activity, the reader should be able to:

• Explain the epidemiology and risk factors of venous thromboembolism (VTE) in cancer
• Summarize current evidence-based guidelines for prevention and treatment of VTE in cancer, with special attention to the differences and similarities across guidelines
• Discuss key data from randomized clinical trials of low-molecular-weight heparins in prevention of recurrent VTE in cancer
• Describe emerging strategies in VTE prophylaxis and treatment

SPONSOR
This activity is sponsored by Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.

INSTRUCTIONS FOR CREDIT

1. Read the article in its entirety 
2. Select “Click here to complete the posttest and obtain a CE certificate online”
3. Complete and submit the CE posttest and CE Activity Evaluation
4. Print your Statement of Completion

PHARMACIST DESIGNATION 
Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-059-H01-P.

This activity is provided free of charge to participants. Upon completion of the evaluation and scoring 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the certificate for your records.

FACULTY DISCLOSURES
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship( s) they might have with the manufacturer( s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

• Paul Dobesh, PharmD, FCCP, BCPS, is a consultant to Ortho-McNeil and sanofi-aventis.
• Gary M. Owens, MD, is a consultant to Auxilium, Biosense Webster, Centocor Ortho Biotech, Eli Lilly, Genentech, and Novartis.
• Gary C. Yee, PharmD, FCCP, BCOP, is on the advisory board for Amgen.
• Nancy Nesser, JD, PharmD, a reviewer for MLI, has nothing to disclose.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.

DISCLAIMER
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Trade names used in this supplement are for the learner’s reference only. No promotion of or bias toward any product should be inferred.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from sanofi-aventis.